You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百济神州(06160.HK)上半年劲收3.21亿美元同比大增276.32%
格隆汇 08-09 08:12

格隆汇8月9日丨百济神州(06160.HK)公布,截至2019年6月30日的六个月,实现总收入3.21亿美元,同比增长276.32%;归属于百济神州的净亏损2.53亿美元,同比减少3.16%;每股净亏损0.33美元。

公告称,2019年第二季度,公司在各项业务领域继续展现强劲的发展势头。公司公布了多项临床试验的积极进展,并在多项血液瘤以及实体瘤适应症中,完成了五项3期或关键性临床试验的患者入组,并启动了三项新的3期临床试验,希望能够为广大癌症患者的治疗带来深远的影响。公司相信有能力继续推动各项后期临床试验,包括替雷利珠单抗的临床项目。

研发方面,截至2019年6月30日的第二季度研发费用为2.2876亿美元,相比2018年同期的1.6425亿美元。

研发费用的增加主要归因于开展的和新启动的晚期关键性临床试验支出的增加、临床后期候选药物的注册登记和商业发布准备、产品上市前活动和供应相关的生产成本。

此外,公司就BioAtla合作协定支出了2000万美元的预付款。研发费用的总体增加还归因于员工股权奖励支出的增加,截至2019年6月30日的第二季度股权奖励支出为1815万美元,相比2018年同期的1072万美元。该增加主要由于员工人数的增长。

公司表示,2019年接下来的时间以及2020年将是百济神州历史上充满变革的一个阶段,将在研发、商业化和生产方面迎来多项里程碑时间。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account